Definium Therapeutics
DFTX
35.09
-0.53
-1.49%
Definium Therapeutics
US · DFTX
#2132 by market cap
Listed 1970
35.09
-0.53
-1.49%
Live - 5344 symbols - heartbeat 167s ago
· 2026-10-08 07:26
Pre-market
34.74
-1.00%
After-hours
35.07
-0.06%
Overnight
35.86
+2.19%
- Market cap
- 4.71B
- P/E (TTM)i
- -10.23
- P/Bi
- 5.13
- EPSi
- -2.06
- Div yieldi
- 0.00%
- 52W posi
- 63%
Reader sentiment
Are you bullish or bearish on DFTX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 14 analysts
Buy
Avg price target
73.36 +109.1%
Price target rangecurrent 35.09
Low55.00
Avg73.36
High91.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-19 | LifeSci Capital | -- | BUY | 78.00 |
| 2026-09-15 | CCORF | -- | BUY | 78.00 |
| 2026-09-15 | JonesTrading | -- | BUY | 90.00 |
| 2026-09-15 | Maxim Group | -- | BUY | 55.00 |
| 2026-09-15 | Baird | -- | BUY | 79.00 |
| 2026-09-15 | Stifel | -- | BUY | 67.00 |
| 2026-09-15 | H.C. Wainwright | -- | BUY | 70.00 |
| 2026-09-14 | LifeSci Capital | -- | BUY | 78.00 |
| 2026-09-14 | BofA Securities | -- | BUY | 91.00 |
| 2026-09-14 | Needham | -- | BUY | 66.00 |
| 2026-09-14 | H.C. Wainwright | -- | BUY | 70.00 |
| 2026-09-14 | Oppenheimer | -- | BUY | 75.00 |
| 2026-09-11 | RBC Capital | -- | BUY | 66.00 |
| 2026-09-08 | LifeSci Capital | -- | BUY | 75.00 |
| 2026-09-02 | CCORF | -- | BUY | 64.00 |
| 2026-08-31 | Wells Fargo | -- | BUY | 72.00 |
| 2026-08-31 | Stifel | -- | BUY | 60.00 |
| 2026-08-18 | BofA Securities | -- | BUY | 75.00 |
| 2026-08-17 | Piper Sandler | -- | BUY | 75.00 |
| 2026-08-17 | BofA Securities | -- | BUY | 75.00 |
| 2026-08-13 | CCORF | -- | BUY | 64.00 |
| 2026-08-13 | Wells Fargo | -- | BUY | 72.00 |
| 2026-08-13 | JonesTrading | -- | BUY | 90.00 |
| 2026-08-13 | Maxim Group | -- | BUY | 55.00 |
| 2026-08-13 | Jefferies | -- | BUY | 65.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | After close | ±23.43% | +0.00% (in line) |
| 2026/Q1 | 2026-05-07 | After close | ±10.00% | -4.96% (in line) |
| 2025/Q4 | 2026-02-26 | After close | -- | +0.93% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:26:40 · For reference only, not investment advice and not tailored to your situation.